12345...102030...


Hopes of breakthrough for psoriatic arthritis patients after Sanger Institute and Oxford University discovery – Cambridge Independent

A third of patients with the skin condition psoriasis develop psoriatic arthritis, for which are some treatments but no cure.

The long-term condition, which causes affected joints to become swollen, stiff and painful, can worsen over time. In the worst cases, it can permanently damage joints, meaning surgery is required.

But there was new hope for those with the condition on Monday, when a study was published showing psoriatic arthritis may be activated by the same trigger in different patients.

The research by the Wellcome Sanger Institute and University of Oxford gives the strongest evidence yet of a single cause for the disease after identifying high levels of a specific receptor in immune cells from patients.

It could help scientists find the exact molecular trigger, which would raise hopes of finding a targeted treatment.

The researchers used single cell technology and machine learning to analyse thousands of individual immune cells from fluid drained from the knees of patients with psoriatic arthritis.

Dr Hussein Al-Mossawi, honorary research associate at the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS) at the University of Oxford, said: Our data suggest that psoriatic arthritis doesnt just appear out of nowhere. Each receptor is like a unique lock that recognises a molecular key and we discovered, that across the patients, they are recognising a common molecule.

This gives the first evidence that the T cells are seeing and reacting to the same molecule, which acts as a trigger for the disease. We dont know the exact culprit yet, but this is a great step forward in understanding the disease.

Dr Sam Behjati, group leader and Wellcome Trust intermediate clinical fellow at the Wellcome Sanger Institute , said: Our study produced the largest single cell dataset from psoriatic arthritis patients to date.

It is helping us to understand the intricate mechanisms behind psoriatic arthritis, including starting to unravel the signals that tell the T cells to cross over into the joint fluid.Imagine the cells as train passengerswith a ticket that tells them at which station to get off - the single cell data is allowing us to read that destination for each cell, and understand the signals.

Paul Bowness, professor of experimental rheumatology at NDORMS said: Our findings indicate that specific T cells are likely to be targeted to enter the joint, where they are triggered to expand, creating inflammation and causing psoriatic arthritis.

The next stage of research will be to find the key that is unlocking the disease in patients - from the signals that direct cells to the joint, to what then triggers them to expand. If we can understand these, we could move towards creating therapies that would prevent this, potentially providing a cure.

Read more

Cancer immunotherapy boost as Sanger Institute and University of Cambridge reveal role of immune cell steroids

Fresh hope of new cancer and autoimmune disease therapies as Wellcome Sanger Institute creates map of thymus gland

Babraham Institute and Sanger scientists find dark matter switch is key to inflammatory diseases

See the original post:

Hopes of breakthrough for psoriatic arthritis patients after Sanger Institute and Oxford University discovery - Cambridge Independent

Greater Joint and Skin Improvement With Ixekizumab vs Adalimumab in Patients With Psoriatic Arthritis – Rheumatology Advisor

Among patients with psoriatic arthritis (PsA), ixekizumab may be superior to adalimumab in terms of joint and skin improvement, according to study results published in Annals of the Rheumatic Diseases.

Results of the SPIRIT head-to-head trial indicated that ixekizumab was superior to adalimumab with regard to the achievement of the American College of Rheumatology (ACR)50 and Psoriasis Area and Severity Index (PASI)100 responses at 24 weeks..

The 52-week, multicenter, phase 3b/4, open-label, randomized, blinded-assessor study (ClinicalTrials.gov Identifier: NCT03151551) aimed to investigate the efficacy and safety of ixekizumab compared with adalimumab in adults with PsA. Patients with inadequate response to conventional synthetic disease-modifying antirheumatic drugs (DMARDs) and no previous exposure to biologic DMARDs were randomly assigned 1:1 to receive either ixekizumab or adalimumab. The primary outcome was superiority of ixekizumab to adalimumab according to ACR50 and PASI100 responses after 24 weeks. Prespecified outcomes after 52 weeks included musculoskeletal, psoriasis, quality of life outcomes, and safety.

The study cohort included 566 patients, of whom 283 received ixekizumab and 283 received adalimumab. Of the total cohort, 246 participants (87%) who received ixekizumab and 237 (84%) who received adalimumab completed the 52-week study visit.

At week 52, treatment with ixekizumab vs adalimumab was associated with a higher percentage of patients achieving both ACR50 and PASI100 (39.2% vs 26.1%, respectively; P <.001). Differences between the groups were evident after 8 weeks, and maintained throughout the study. A significantly higher percentage of patients who received ixekizumab achieved PASI100 (64.3% vs 41.3%, respectively; P .001). However, similar response rates for ACR50, ACR20, and ACR70 were observed with ixekizumab and adalimumab, as were other efficacy outcomes, including treat-to-target outcomes, enthesitis, and dactylitis resolution.

When used as monotherapy for 52 weeks, ixekizumab was superior to adalimumab for simultaneous achievement of ACR50 and PASI100 (38% vs 19%, respectively; P =.007), and PASI100 responses (66% vs 35%, respectively; P <.001). While response rates were higher with a combination of adalimumab and conventional synthetic DMARDs vs adalimumab monotherapy, response rates for ixekizumab were consistent irrespective of concomitant conventional synthetic DMARD use.

There were no new safety findings for either ixekizumab or adalimumab.

The study had several limitations, including the open-label design, potential assessment bias, and no available data on antidrug antibodies to ixekizumab or adalimumab.

SPIRIT-H2H study comparing ixekizumab [vs] adalimumab is the first fully disclosed direct head-to-head study in PsA; its findings over 52 weeks will inform future treatment recommendations and may impact selection of therapy in bionaive patients with active PsA, the researchers concluded.

Disclosure: This clinical trial was supported by Eli Lilly and Company. Please see the original reference for a full list of authors disclosures.

Reference

Smolen JS, Mease P, Tahir H, et al. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis nave to biological disease-modifying antirheumatic drug: final results by week 52. Published online July 13, 2020. Ann Rheum Dis. doi:10.1136/annrheumdis-2020-217372

Read more:

Greater Joint and Skin Improvement With Ixekizumab vs Adalimumab in Patients With Psoriatic Arthritis - Rheumatology Advisor

Heres how you can control eczema and psoriasis flare-up during changing weather – The Indian Express

By: Lifestyle Desk | New Delhi | Updated: September 22, 2020 10:39:01 pmThe lesions usually occur on cooler places of the skin like the elbows, the knees, the scalp, on the palms, soles, etc. (Source: Pixabay)

The body reacts differently to the changing weather, and those who suffer from skin conditions would know that weather always factors in whenever there is a sudden deterioration of the condition.

Eczema (or dermatitis) is a condition wherein the patient develops severely-itchy lesions with fluid-filled vesicles/oozing during an acute exacerbation phase, and psoriasis is a skin disease wherein the turnover of the skin speeds up. Instead of the average two months, the skin turns over in three or four days, leading to red or pink lesions with silvery-white scaling. The lesions usually occur on cooler places of the skin like the elbows, the knees, the scalp, on the palms, soles, etc.

Dr Smriti Naswa Singh, Consultant Dermatologist, Fortis Hospital, Mulund, says the reason for developing eczema could be external (sun, aero-allergens, some irritant applications, etc.) or internal (familial allergic tendency, endogenous eczema, old age, or a manifestation of other internal diseases like diabetes, chronic liver or kidney disease, cancer, HIV, etc.). While psoriasis and eczema do not spread to others, they do flare up during winters or cooler seasons, since the dryness of the skin increases, leading to more itchiness; when a person scratches, the patches aggravate.

ALSO READ |Home-based care for COVID-19 infection; here are some dos and donts

Dr Singh suggest the following ways to control the outbursts:

* Change of weather to cooler weather makes the skin dry. Applying a moisturizer is key. Moisturizers work best on wet skin and have to be frequently applied throughout the day.

* Itch-scratch is a vicious cycle that needs to be broken to control the exacerbation. So whenever one feels itchy, they should apply moisturizer and not scratch the area. Oral and topical medications help in controlling the itching sensation; do consult a dermatologist for guidance.

* Weather-change is usually associated with an increase in aero-allergens, so those suffering from atopic dermatitis (eczema due to allergic tendency running in family) suffer more. They should try to keep their immunity high by consuming fruits and vegetables, taking adequate rest and staying away from common allergens like dust, sweat, synthetic clothes, wool etc. Cotton clothing is the preferred choice.

* Stress is known to exacerbate both psoriasis and eczema, and hence, should be avoided. Adequate rest and work-life balance are important factors.

ALSO READ |What patients on dialysis need to know about controlling diabetes

* Psoriasis is directly linked to metabolic syndrome. Psoriatic patients have a tendency to be more prone to lifestyle diseases like diabetes, hypertension and altered lipid profile. If the person indulges in oily foods, junk foods, gains weight, does not exercise, psoriasis can worsen. Adopting appropriate lifestyle measures will help in such scenarios.

* During the COVID-19 pandemic, people have been overzealous in washing hands and using hand sanitizers. Detergent strips off the skin from natural moisturizing factors for at least 6 hours before the skin replenishes it. Sanitizers can be irritant/allergic to sensitive skin. Refrain from excessive use of soaps/washing detergents/sanitizers. Applying a moisturizer after washing/cleaning your hands/feet will help prevent the aggravation.

A patient can prevent exacerbation of psoriasis and eczema by keeping in mind the aforementioned methods. But for treatment of the lesions, one needs a carefully-formulated, tailor-made prescription of oral/systemic and topical medications. You should visit your dermatologist at first instance of the flare-up, or when the rashes are noted; these can be treated with topical cream formulations alone.

ALSO READ |How do COVID-19 triggered blood clots affect the heart? A doctor answers

If unfortunately, there is delay and the disease becomes extensive, oral medications may be required and sometimes, especially in psoriasis and certain cases of endogenous eczemas, there may be a need for control of acute exacerbation. We call such cases as acute skin failure with risk of hypovolemia, infection, electrolyte imbalance and thermal dysregulation, Dr Singh explains.

For more lifestyle news, follow us: Twitter:lifestyle_ie|Facebook:IE Lifestyle| Instagram:ie_lifestyle

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Lifestyle News, download Indian Express App.

IE Online Media Services Pvt Ltd

Visit link:

Heres how you can control eczema and psoriasis flare-up during changing weather - The Indian Express

Psoriasis Biologics and Heart Disease Risk – Everyday Health

People with psoriasis who are on biologic therapies may get an added boost to their overall health: a reduced risk of heart disease.

According to a study published in the September 2020 issue of the journal Circulation: Cardiovascular Imaging, people who received biologics like adalimumab and ustekinumab for one year to manage their psoriasis had lower levels of a type of coronary plaque called lipid-rich necrotic core (LRNC) compared with people who didnt receive the drugs.

LRNC has been linked with higher risk of heart attack and stroke in people with coronary artery disease.

The Centers for Disease Control and Prevention (CDC) describes plaque as cholesterol deposits that accumulate on the walls of arteries, causing blockages that can lead to coronary artery disease. Coronary artery disease is the most common form of heart disease in the United States, affecting an estimated 18 million people, the CDC says.

[Our] current hypothesis is that treatment of psoriasis may result in a lowering of the risk of cardiovascular disease over time, explains Joel M. Gelfand, MD, director of the Psoriasis and Phototherapy Treatment Center at University of Pennsylvanias Perelman School of Medicine Philadelphia, who was one of the coauthors of the new study.

RELATED: The Consumers Guide to Biologics for Psoriasis

It seems biologic therapy as well as phototherapy two commonly used treatments for psoriasis may both work to reduce levels of LRNC in the blood. LRNC is among several leading biomarkers (measurable signs) that can predict future heart attacks, Dr. Gelfand says.

Biologics, which target specific areas of the immune system, have been used for psoriasis treatment since the early 2000s. The biologics used to treat psoriatic disease block the action of a specific type of immune cell a T cell or proteins in the immune system, such as tumor necrosis factor-alpha (TNF-alpha), interleukin 17-A, or interleukins 12 and 23, according to the National Psoriasis Foundation.

TNF-alpha and the interleukins all play a major role in psoriasis and psoriatic arthritis.

RELATED: 7 Signs You May Need to Change Your Psoriasis Treatment

For the new study, Gelfand and his colleagues enrolled 209 people with psoriasis who had not yet been treated with biologics. Roughly one-half were prescribed biologic therapies to treat their condition, while the rest were not.

LRNC for people in both groups was assessed using coronary computed tomography angiography, with measurements taken at the beginning of the study and, again, one year later.

On average, those who received biologic therapy saw their LRNC decline from 3.12 square millimeters (mm2) to 2.97 mm2 or about 5 percent. Conversely, those who werent on biologic therapy saw LRNC increase from 3.12 to 3.34 mm2, on average a 6 percent rise.

RELATED: 8 Health Conditions Linked to Psoriasis

Although larger studies are needed to confirm the positive effects of biologics on LRNC and heart disease risk, the findings are exciting, Gelfand says, because recent research suggeststhat people with psoriasis are at increased risk for heart disease.

And this risk is more clinically significant in those with more severe skin disease, Gelfand notes. People with psoriasis should be screened for traditional cardiovascular risk factors such as high blood pressure, diabetes, and high cholesterol, and they should adopt a heart-healthy lifestyle whether theyre on biologics or not.

RELATED: Psoriasis and Heart Disease: The Hidden Connection

Go here to read the rest:

Psoriasis Biologics and Heart Disease Risk - Everyday Health

Psoriasis Treatment Market Size, Analytical Overview, Key Players, Growth Factors, Demand, Trends And Forecast to 2027 – The Daily Chronicle

Fort Collins, Colorado Reports Globe recently added the Psoriasis Treatment Market Research Report that provides a thorough investigation of the market scenario of the market size, share, demand, growth, trends, and forecast from 2020-2027. The report covers the impact analysis of the COVID-19 pandemic. COVID-19 pandemic has affected the export-import, demands, and trends of the industry and is expected to have some economic impact on the market. The report provides a comprehensive analysis of the impact of the pandemic on the overall industry and offers insights into a post-COVID-19 market scenario.

The report primarily mentions definitions, classifications, applications, and market overview of the Psoriasis Treatment industry. It also covers product portfolios, manufacturing processes, cost analysis, structures, and gross margin of the industry. It also provides a comprehensive analysis of the key competitors and their regional spread and market size.

Get a sample of the report @ https://reportsglobe.com/download-sample/?rid=65209

Competitive Analysis:

The report provides a comprehensive analysis of the companies operating in the Psoriasis Treatment market, along with their overview, business plans, strengths, and weaknesses to provide a substantial analysis of the growth through the forecast period. The evaluation provides a competitive edge and understanding of their market position and strategies undertaken by them to gain a substantial market size in the global market.

Key features of the Report:

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

Request a Discount on the report @ https://reportsglobe.com/ask-for-discount/?rid=65209

Additionally, the report is furnished by the advanced analytical data from SWOT analysis, Porters Five Forces Analysis, Feasibility Analysis, and Investment Return Analysis. The report also provides a detailed analysis of the mergers, consolidations, acquisitions, partnerships, and government deals. Along with this, an in-depth analysis of current and emerging trends, opportunities, threats, limitations, entry-level barriers, restraints and drivers, and estimated market growth throughout the forecast period are offered in the report.

Market Breakdown:

The market breakdown provides market segmentation data based on the availability of the data and information. The market is segmented on the basis of types and applications.

Psoriasis Treatment Market Segmentation, By Type

Psoriasis Treatment Market Segmentation, By Applications

Request customization of the report @https://reportsglobe.com/need-customization/?rid=65209

The report provides additional analysis about the key geographical segments of the Psoriasis Treatment Market and provides analysis about their current and previous share. Current and emerging trends, challenges, opportunities, and other influencing factors are presented in the report.

Regional analysis includes an in-depth study of the key geographical regions to gain a better understanding of the market and provide an accurate analysis. The regional analysis coversNorth America, Latin America, Europe, Asia-Pacific, and the Middle East & Africa.

Objectives of the Report:

To learn more about the report, visit @ https://reportsglobe.com/product/global-psoriasis-treatment-assessment/

Thank you for reading our report. To learn more about report details or for customization information, please contact us. Our team will ensure that the report is customized according to your requirements.

How Reports Globe is different than other Market Research Providers

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email:[emailprotected]

Web:reportsglobe.com

Read the rest here:

Psoriasis Treatment Market Size, Analytical Overview, Key Players, Growth Factors, Demand, Trends And Forecast to 2027 - The Daily Chronicle

Immune system may trigger anxiety in response to infection – Medical News Today

A new study in mice adds to the evidence suggesting that the immune system not only attacks invading pathogens but can also influence mood.

Over the past few years, scientists have discovered some intriguing links between immunity and the mind.

One of the immune signaling molecules, or cytokines, that mediates these links is called interleukin-17a (IL-17a).

IL-17a plays a role in psoriasis, which is an autoimmune skin condition, but it may also contribute to the depression that many people experience. Indeed, a study involving a mouse model of psoriasis found that IL-17a caused depression-like symptoms.

In humans, researchers have also linked the molecule to treatment resistant depression.

Research in mice has even implicated IL-17a in the development of autism.

The brain and the body are not as separate as people think, says Prof. Jonathan Kipnis, a neuroscientist at the Washington University School of Medicine in St Louis, MO.

While working at the University of Virginia School of Medicine in Charlottesville, Prof. Kipnis and colleagues found that IL-17a causes anxiety-like behavior in mice.

We are now looking into whether too much or too little of IL-17a could be linked to anxiety in people, says Prof. Kipnis.

The scientists have published the results of their mouse study in the journal Nature Immunology. Kalil Alves de Lima, a postdoctoral researcher who is also now at the University of Washington, led the research.

Immune cells called gamma-delta T cells produce IL-17a. The cells are present in the meninges, which are the membranes surrounding the brain and spinal cord.

To determine what effect IL-17a might have on behavior, the scientists studied mice whose gamma-delta T cells did not produce any IL-17a and mice who lacked the cells completely.

They put the mice through standard tests of memory, social behavior, foraging, and anxiety. The mice performed just as well as normal mice on all tests apart from two that measure anxiety levels.

In those tests, the mice who lacked gamma-delta T cells or did not produce any IL-17a were more likely to explore open areas. In the wild, this kind of behavior would put them at greater risk of being eaten by predators.

The researchers interpreted this as a sign of reduced anxiety in animals without IL-17a signaling in their central nervous system.

Next, the scientists investigated how the signal affects neurons in their brains. They found receptors for IL-17a on a type of stimulatory nerve cell called a glutamatergic neuron.

When they genetically manipulated the neurons to prevent them from making these receptors, the mice exhibited less anxiety-like behavior.

Previous animal research has revealed a multitude of possible links between bacteria living in the gut and behavior, including anxiety-like behaviors.

This connection is known as the gut-brain axis, and scientists have proposed the immune system as one possible way that messages pass between them.

To investigate the role of IL-17a in the gut-brain axis, Alves de Lima and colleagues injected the mice with lipopolysaccharide. This is a toxin that bacteria produce. It provokes a strong immune reaction.

In response to the injection, gamma-delta T cells in the meninges surrounding the animals brains produced more IL-17a.

In another experiment, when the researchers treated the mice with antibiotics to kill the bacteria in their guts, the animals produced less IL-17a.

Together, the results of these experiments suggest that the immune system has evolved not only to fight infection but also to adjust behavior to keep animals safe while they are in a weakened state.

Selecting special molecules to protect us immunologically and behaviorally at the same time is a smart way to protect against infection. This is a good example of how cytokines, which basically evolved to fight against pathogens, also are acting on the brain and modulating behavior.

Kalil Alves de Lima

The team is now investigating how gamma-delta T cells in the meninges surrounding the brain can detect the presence of bacteria elsewhere in the body.

The researchers are also looking into exactly how IL-17a signaling in the brain changes behavior.

In their paper, they conclude:

Our findings provide new insights into the neuroimmune interactions at the meningealbrain interface and support further research into new therapies for neuropsychiatric conditions.

Although the physiology of mice and humans is very similar, scientists need to carry out much more research to explore the possible links between the human immune system and mood.

Read the original:

Immune system may trigger anxiety in response to infection - Medical News Today

Modifiable Risk Factors Associated With Transition From Psoriasis to Psoriatic Arthritis – AJMC.com Managed Markets Network

It may be possible to modify some lifestyle and environmental factors to reduce the risk of patients transitioning from psoriasis to psoriatic arthritis.

Psoriatic arthritis (PsA) occurs in approximately one-third of patients with psoriasis, but it may be possible to modify some lifestyle and environmental factors to reduce the risk of patients transitioning from psoriasis to PsA, according to research published in Journal of the American Academy of Dermatology.

PsA causes pain, swelling, and joint stiffness, and it is associated with impaired quality of life, a greater risk of comorbidities, and higher health care expenditures. The underlying events that cause the transition to PsA are not well understood, but current thought is that heredity and the environment both play a role.

determining the modifiable factors associated with transition to PsA among patients with psoriasis may provide a unique opportunity for early prevention and deepen our understanding of the etiology of PsA as well, the authors explained.

The researchers conducted a systematic search of PubMed, EMBASE, and Cochrane Library for observational studies reporting lifestyle or environmental factors for PsA onset in patients with psoriasis. The included 16 studies in their analysis. The studies originated from the United Kingdom (n = 6), Canada (n = 4), the United States (n = 4), Japan (n = 1), and Singapore (n = 1) and they included 322,967 patients.

Nine of the studies assessed the association between smoking and PsA. There were 8 studies on alcohol consumption in patients with psoriasis. Eight studies investigated the risk of PsA onset by body mass index (BMI). A total of 5 studies analyzed physical trauma and the presence of PsA.

The meta-analysis of BMI found a dose-dependent increase in the risk of developing PsA for patients with psoriasis. The risk increased 75% for patients with obesity. Despite the potential causal association between PsA and obesity, the underlining mechanisms are not completely understood, the authors wrote. They conjectured that chronic low-grade inflammation status in patients with obesity represents an increase in inflammatory cytokines and an alternation in adipokines, which might lead to the development of PsA in predisposed individuals.

The association between smoking and risk of PsA among patients with psoriaris remains unclear due to severely conflicting findings. One case-control study found a protective relationship, but more recently updated research using the same database showed smoking status was unrelated to PsA risk. However, another study using a large cohort of women found an elevated risk. The authors determined there was no association between smoking status (whether patients had ever smoked, currently smoked, or were past smokers) and the risk of developing PsA.

The authors did note a significant increase in the risk of developing PsA in patients with psoriasis who had had experienced traumatic injury. Individuals with psoriasis who are exposed to physical trauma, such as fracture, may transition from psoriasis to PsA.

The researchers did note their findings require caution since they were interpreting evidence from observational studies, which can be more biased than randomized controlled trials. In addition, not all the studies adjusted enough for potential confounders.

The results of the study highlight a need to strengthen public health to promote awareness and endeavor to reduce the risk of transition to PsA in psoriasis patients, and furthermore deepen our understanding of the etiology of PsA, the authors concluded.

Reference

Xie W, Huang H, Deng X, Gao D, Zhang Z. Modifiable lifestyle and environmental factors associated with onset of psoriatic arthritis in patients with psoriasis: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol. Published online August 19, 2020. doi:10.1016/j.jaad.2020.08.060

Go here to read the rest:

Modifiable Risk Factors Associated With Transition From Psoriasis to Psoriatic Arthritis - AJMC.com Managed Markets Network

Global Psoriasis Treatment Market by Type, Treatment Method, Region and Country (2020 Edition): Market Insights and Outlook Post COVID-19 Pandemic…

DUBLIN--(BUSINESS WIRE)--The "Global Psoriasis Treatment Market - Analysis by Type, by Treatment Method, by Region, by Country (2020 Edition): Market Insights and Outlook Post Covid-19 Pandemic (2020-2025)" report has been added to ResearchAndMarkets.com's offering.

Global Psoriasis Treatment Market was valued at USD 16.7 billion in the year 2019.

Rising prevalence of psoriasis affected people, rise in research and investments in developing biological treatment, rise in awareness of psoriasis coupled with the rising demand for healthcare products are the major factors impelling the market growth. Major growth in the forecast period is likely to be demonstrated from the various drugs that are in the clinical stages and would be available commercially in the next 3-5 years. This includes among others, the most promising ARQ-154 Foam for scalp psoriasis, from the US biotechnology company, Arcutis, which has the potential to become a billion-dollar opportunity for the treatment of psoriasis.

Genetic disposition, rising geriatric population and increasing government initiatives creating psoriasis awareness have been anticipated to infuse growth in the market for Psoriasis during the forecasting period of 2020-2025. Factors such as rising geriatric population, practice of unhealthy lifestyle such as heavy consumption of alcohol, smoking tobacco, enaction of immunity framework, stress and sunburn are crucial factors are supposed to trigger Psoriasis and Psoriasis arthritis that is consequently accelerating the demand for Psoriasis treatment and medication.

The growth of the market is hampered in 2020 due to the occurrence of coronavirus pandemic in which all worldwide business activities are put at hold for the first few months of the year. IPC recommended physicians to discontinue or postpone use of immunosuppressant medications for the psoriasis patients, which is negatively affecting the Psoriasis drugs market growth. However, as per National Psoriasis Foundation the Medicare extended its inclusion of telehealth administrations in amid COVID-19 pandemic due to which the treatment has been resumed and the drug market has been supported in few first few months of 2020 that are anticipated to recover and accelerate the demand for the treatment in the coming years.

Under the Type Segment, Plaque Psoriasis is the most common type of psoriasis and dominates the overall psoriasis market. The developing number of advanced medicines for the treatment of plaque psoriasis by the key players is augmenting the demand for enhanced medication.

The continual research and development in a number of biologics and biosimilars by the drug developing companies are expected to propel market demand of biologics treatment method for psoriasis. Among the regions, North America is followed by and Europe and Asia Pacific. Asia Pacific region is the most attractive region for the growth of Psoriasis treatment owing large targeted population base coupled with increasing healthcare spending, prevalence of psoriasis or psoriatic arthritis patients, rise in government contribution and awareness programs.

Scope of the Report

Key Topics Covered

1. Report Scope and Methodology

1.1 Scope of the Report

1.2 Research Methodology

1.3 Executive Summary

2. Strategic Recommendations

3. Global Psoriasis Treatment Market: Product Outlook

4. Global Psoriasis Treatment Market: Sizing, Growth and Forecast

4.1 Market Size, By Value, Year 2015-2025

5. Global Psoriasis Treatment Market Segmentation By Type (By Value)

5.1 Competitive Scenario of Global Psoriasis Market - By Type (2019 & 2025)

5.2 Plaque Psoriasis- Market Size and Forecast (2020-2025)

5.3 Inverse Psoriasis- Market Size and Forecast (2020-2025)

5.4 Guttate Psoriasis- Market Size and Forecast (2020-2025)

5.5 Pustular Psoriasis- Market Size and Forecast (2020-2025)

5.6 Erythrodermic Psoriasis- Market Size and Forecast (2020-2025)

6. Global Psoriasis Market Segmentation By Treatment Method (By Value)

6.1 Competitive Scenario of Global Psoriasis - By Treatment Method (2019 & 2025)

6.2 Biologics - Market Size and Forecast (2020-2025)

6.3 Systemic Treatment- Market Size and Forecast (2020-2025)

6.4 Topical Treatment- Market Size and Forecast (2020-2025)

6.5 Others - Market Size and Forecast (2020-2025)

7. Global Psoriasis Treatment Market: Regional Analysis

7.1 Competitive Scenario of Global Psoriasis Market : By Region (2019 & 2025)

8. North America Psoriasis Market: Segmentation By Type, By Treatment Method (2020-2025)

8.1 North America Psoriasis Treatment Market: Size and Forecast (2020-2025)

8.2 North America Prominent Companies in Psoriasis Market

8.3 Market Segmentation By Type (Plaque Psoriasis, Inverse Psoriasis, Guttate Psoriasis, Pustular Psoriasis- & Erythrodermic Psoriasis)

8.4 Market Segmentation By Treatment Method (Biologics, Systemic Treatment, Topical Treatment & Others)

8.5 North America Psoriasis Market: Country Analysis

8.6 Market Opportunity Chart of North America Psoriasis Market - By Country, By Value (Year-2025)

8.7 Competitive Scenario of North America Psoriasis Market: By Country (2019 & 2025)

8.8 United States Psoriasis Market: Size and Forecast (2020-2025)

8.9 United States Psoriasis Market Segmentation By Type, By Treatment Method (2020-2025)

8.10 Canada Psoriasis Market: Size and Forecast (2020-2025)

8.11 Canada Psoriasis Market Segmentation By Type, By Treatment Method (2020-2025)

9. Europe Psoriasis Market: Segmentation By Type, By Treatment Method (2020-2025)

10. Asia Pacific Psoriasis Market: Segmentation By Type, By Treatment Method (2020-2025)

11. Global Psoriasis Treatment Market Dynamics

11.1 Global Psoriasis Market Drivers

11.2 Global Psoriasis Market Restraints

11.3 Global Psoriasis Market Trends

12. Market Attractiveness

12.1.1 Market Attractiveness Chart of Global Psoriasis Treatment Market - By Type (Year 2025)

12.1.2 Market Attractiveness Chart of Global Psoriasis Market - By Treatment Method (Year 2025)

12.1.3 Market Attractiveness Chart of Global Psoriasis Treatment Market - By Region, By Value, (Year-2025)

13. Competitive Landscape

13.1 Psoriasis Pipeline Analysis

13.2 Market Share Analysis

14. Company Profiles (Business Description, Financial Analysis, Business Strategy)

14.1 UCB

14.2 Sun Pharmaceutical Industries Ltd.

14.3 Boehringer Ingelheim

14.4 Almirall

14.5 Bausch Health

14.6 Abbvie Inc.

14.7 Eli Lilly and Company

14.8 Pfizer Inc.

14.9 Amgen Inc.

14.10 Johnson & Johnson

For more information about this report visit https://www.researchandmarkets.com/r/lfp8z9

Read the original here:

Global Psoriasis Treatment Market by Type, Treatment Method, Region and Country (2020 Edition): Market Insights and Outlook Post COVID-19 Pandemic...

Nonadherence to Treatment and Patient-Reported Outcomes of Psoriasis D | PPA – Dove Medical Press

Qiaolin Wang,1 3 Yan Luo,1 3 Chengzhi Lv,4 Xuanwei Zheng,1 3 Wu Zhu,1 3 Xiang Chen,1 3 Minxue Shen,1 3,5 Yehong Kuang1 3

1Department of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, Peoples Republic of China; 2National Clinical Research Center for Geriatric Disorders (Xiangya Hospital), Changsha 410008, Peoples Republic of China; 3Hunan Engineering Research Center of Skin Health and Disease, Hunan Key Laboratory of Skin Cancer and Psoriasis (Xiangya Hospital), Changsha 410008, Peoples Republic of China; 4Department of Psoriasis, Dalian Dermatosis Hospital, Dalian, Liaoning 116021, Peoples Republic of China; 5Department of Social Medicine and Health Management, Xiangya School of Public Health, Central South University, Changsha 410078, Peoples Republic of China

Correspondence: Yehong Kuang; Minxue ShenXiangya Hospital, Central South University, 87 Xiangya Road, Changsha, Hunan, Peoples Republic of ChinaEmail yh_927@126.com; shenmx1988@csu.edu.cn

Purpose: The COVID-19 epidemic has caused difficulties in continuous treatment for patients with chronic diseases and resulted in nonadherence to treatment and adverse health outcomes. This study aimed to investigate the associations of nonadherence to treatment with patient-reported outcomes of psoriasis during the COVID-2019 epidemic.Methods: A cross-sectional study among Chinese patients with psoriasis was conducted through a web-based questionnaire survey during 25 Feb 2020 and 6 Mar 2020. Demographic and clinical data, nonadherence to treatment, and patient-reported outcomes were collected. The outcomes included deterioration of the disease condition, perceived stress, and symptoms of anxiety and depression. Logistic regression was used to investigate the associations.Results: A total of 926 questionnaires were collected. A total of 634 (68.5%) reported nonadherence to treatment, and worse adherence was found among patients receiving systemic treatment (adjusted odds ratio [AOR]: 2.67; 95% CI: 1.40 5.10) and topical treatment (AOR: 4.51; 95% CI: 2.66 7.65) compared to biological treatment. Nonadherence to treatment (less than two weeks and more than two weeks) wassignificantly associated with deterioration of psoriasis (aOR: 2.83 to 5.25), perceived stress (AOR: 1.86 to 1.57), and symptoms of anxiety (AOR: 1.42 to 1.57) and depression (AORs: 1.78). Subgroup analysis by treatment showed consistent results in general.Conclusion: Nonadherence to treatment was associated with the aggravation of psoriasis conditions, perceived stress, and symptoms of anxiety and depression.

Keywords: psoriasis, coronavirus disease 2019, patient-reported outcome, treatment adherence

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read the original post:

Nonadherence to Treatment and Patient-Reported Outcomes of Psoriasis D | PPA - Dove Medical Press

Fourteen small molecule and biological agents for psoriatic arthritis: A network meta-analysis of randomized controlled trials – DocWire News

Background:The comparative efficacy and safety of small molecule and biological agents in the treatment of psoriatic arthritis (PsA) remain unknown.

Objectives:To compare the efficacy and safety of 14 small molecule and biological agents by network meta-analysis (NMA).

Methods:Relevant randomized controlled trials involving biological treatments for PsA were identified by searching PubMed, Cochrane Library, EMBASE, Web of Science, and Clinicaltrials.gov and by manual retrieval, up to June 2018. NMA was conducted with Stata 14.0 based on the frequentist method. Effect measures were odds ratios (ORs) with 95% confidence intervals (CIs). Intervention efficacy and safety were ranked according to the surface under the cumulative ranking curve (SUCRA).

Results:A total of 30 studies involving 10,191 adult subjects were included. According to NMA, 20% improvement in modifed American College of Rheumatology response criteria (ACR20) response, Psoriasis Area and Severity Index 75 (PASI75) response, and serious adverse events rate (SAEs) were observed. In direct comparisons, most of the biologics performed better than placebo in terms of ACR20 response rate and PASI75 response rate. Additionally, all medicines were comparable to placebo in terms of SAEs except secukinumab. In terms of mixed comparisons, with regard to the ACR20 response, etanercept (ETN) and infliximab (IFX) were more effective than golimumab (GOL), with ORs of 3.33 (95% CI: 1.17-9.48) and 1.24 (95% CI: 0.61-2.52), respectively. For PASI75 response, IFX was superior to certolizumab pegol (OR = 10.08, 95% CI: 1.54-75.48). In addition, these medicines were comparable to each other in terms of SAEs. ETN and IFX were shown to have the most favorable SUCRA for achieving improved ACR20 and PASI75 responses, respectively, while ABT-122 exhibited the best safety according to the SUCRA for SAEs. Considering both the efficacy (ACR20, PASI75) and safety (SAEs), GOL, ETN, and IFX are the top 3 treatments.

Conclusions and implications:Direct and indirect comparisons and integrated results suggested that the 3 anti- tumor necrosis factor - biologics (GOL, ETN, and IFX) can be considered the best treatments for PsA after comprehensive consideration of efficacy and safety.

See the original post:

Fourteen small molecule and biological agents for psoriatic arthritis: A network meta-analysis of randomized controlled trials - DocWire News

Psoriasis is a debilitating condition: Try Ayurveda to deal with symptoms – TheHealthSite

Psoriasis is a relatively common skin disorder where skin cells multiply almost 10 times faster than normal. This results in the build-up of bumpy red patches covered with white scales. Though they can grow anywhere, such patches are usually seen on the scalp, elbows, knees, and lower back. In severe cases, it can cover almost the entire body. It is not a contagious condition. It can cause severe itching, bleeding and cracking of skin. Sometimes, it also affects the fingernails and toenails, including discoloration and pitting of the nails. Psoriatic arthritis is also common among people with this condition. It causes pain and swelling in the joints. This is usually a hereditary condition. But stress, allergies and some medications can also trigger this condition. Also Read - Ayurvedic treatment for Psoriasis: Can Panchakarma therapy really help?

Treatment for this condition includes topical application of steroid creams, moisturizers, creams and ointments. Retinoid creams also help deal with the symptoms as can light therapy. This is a log-lasting condition interspersed with flare-ups and long periods of remission. Other than Allopathy, sometimes, alternative healing therapies may also help you deal with the symptoms. Ayurveda, the ancient healing therapy from India, can help you here. Also Read - Turmeric, apple cider vinegar and other home remedies for psoriasis

This healing therapy, which was developed more than 3,000 years ago, uses a combination of diet, exercise, lifestyle changes and some Ayurvedic medicines. Though some experts say that there is no proof that Ayurveda can help, advocates say that it really does help in the treatment of psoriasis. It goes without saying that some Ayurvedic practices, like eating veggies and drinking plenty of water, are healthy for everyone including psoriasis patients. But practices like bloodletting may be unsafe in the wrong hands. So, you must always go to a certified Ayurveda doctor for treatment. Also Read - 5 effective home remedies to treat psoriasis

Ayurveda believes that everyone is made up of five basic elements: Air, earth, fire, ether and water. Together, these elements form life forces called doshas. The three doshas are vata, which is ether and air, pitta, which is fire and water, and Kapha, which is water and earth. According to this healing therapy, psoriasis results from unbalanced vata and kapha doshas. Toxins, stress, and certain foods, like yogurt, seafood, and salty food, can also cause this condition.

In Ayurveda, your treatment will depend on your symptoms and lifestyle. It may include diet changes, specific herbs, massage with specially formulated oils, enemas or laxatives and controlled vomiting. Sometimes, treatment may also involve blood cleansing using herbs or bloodletting, which involves draining blood from your body.

You ma be asked to drink lots of water and eat green, leafy vegetables. Turmeric, which reduces inflammation and has antioxidant properties is an important of treatment here. You may also be asked to apply a paste made from a botanical powder made from the andira araroba tree, mixed with vinegar or lemon juice to psoriasis patches. Olive oil is also used for topical application as is cayenne pepper and aloe vera. Moreover, your therapist may ask you to avoid foods and drinks like alcohol, red meat, spicy food, junk food and acidic foods.

Published : August 8, 2020 6:12 pm | Updated:August 8, 2020 6:20 pm

Continue reading here:

Psoriasis is a debilitating condition: Try Ayurveda to deal with symptoms - TheHealthSite

Psoriasis: Causes, Triggers, Treatment, and More

Psoriasis is a chronic autoimmune condition that causes the rapid buildup of skin cells. This buildup of cells causes scaling on the skins surface.

Inflammation and redness around the scales is fairly common. Typical psoriatic scales are whitish-silver and develop in thick, red patches. Sometimes, these patches will crack and bleed.

Psoriasis is the result of a sped-up skin production process. Typically, skin cells grow deep in the skin and slowly rise to the surface. Eventually, they fall off. The typical life cycle of a skin cell is one month.

In people with psoriasis, this production process may occur in just a few days. Because of this, skin cells dont have time to fall off. This rapid overproduction leads to the buildup of skin cells.

Scales typically develop on joints, such elbows and knees. They may develop anywhere on the body, including the:

Less common types of psoriasis affect the nails, the mouth, and the area around genitals.

According to one study, around 7.4 million Americans have psoriasis. Its commonly associated with several other conditions, including:

There are five types of psoriasis:

Plaque psoriasis is the most common type of psoriasis.

The American Academy of Dermatology (AAD) estimates that about 80 percent of people with the condition have plaque psoriasis. It causes red, inflamed patches that cover areas of the skin. These patches are often covered with whitish-silver scales or plaques. These plaques are commonly found on the elbows, knees, and scalp.

Guttate psoriasis is common in childhood. This type of psoriasis causes small pink spots. The most common sites for guttate psoriasis include the torso, arms, and legs. These spots are rarely thick or raised like plaque psoriasis.

Pustular psoriasis is more common in adults. It causes white, pus-filled blisters and broad areas of red, inflamed skin. Pustular psoriasis is typically localized to smaller areas of the body, such as the hands or feet, but it can be widespread.

Inverse psoriasis causes bright areas of red, shiny, inflamed skin. Patches of inverse psoriasis develop under armpits or breasts, in the groin, or around skinfolds in the genitals.

Erythrodermic psoriasis is a severe and very rare type of psoriasis.

This form often covers large sections of the body at once. The skin almost appears sunburned. Scales that develop often slough off in large sections or sheets. Its not uncommon for a person with this type of psoriasis to run a fever or become very ill.

This type can be life-threatening, so individuals should see a doctor immediately.

Check out pictures of the different types of psoriasis.

Psoriasis symptoms differ from person to person and depend on the type of psoriasis. Areas of psoriasis can be as small as a few flakes on the scalp or elbow, or cover the majority of the body.

The most common symptoms of plaque psoriasis include:

Not every person will experience all of these symptoms. Some people will experience entirely different symptoms if they have a less common type of psoriasis.

Most people with psoriasis go through cycles of symptoms. The condition may cause severe symptoms for a few days or weeks, and then the symptoms may clear up and be almost unnoticeable. Then, in a few weeks or if made worse by a common psoriasis trigger, the condition may flare up again. Sometimes, symptoms of psoriasis disappear completely.

When you have no active signs of the condition, you may be in remission. That doesnt mean psoriasis wont come back, but for now youre symptom-free.

Doctors are unclear as to what causes psoriasis. However, thanks to decades of research, they have a general idea of two key factors: genetics and the immune system.

Psoriasis is an autoimmune condition. Autoimmune conditions are the result of the body attacking itself. In the case of psoriasis, white blood cells known as T cells mistakenly attack the skin cells.

In a typical body, white blood cells are deployed to attack and destroy invading bacteria and fight infections. This mistaken attack causes the skin cell production process to go into overdrive. The sped-up skin cell production causes new skin cells to develop too quickly. They are pushed to the skins surface, where they pile up.

This results in the plaques that are most commonly associated with psoriasis. The attacks on the skin cells also cause red, inflamed areas of skin to develop.

Some people inherit genes that make them more likely to develop psoriasis. If you have an immediate family member with the skin condition, your risk for developing psoriasis is higher. However, the percentage of people who have psoriasis and a genetic predisposition is small. Approximately 2 to 3 percent of people with the gene develop the condition, according to the National Psoriasis Foundation (NPF).

Read more about the causes of psoriasis.

Two tests or examinations may be necessary to diagnose psoriasis.

Most doctors are able to make a diagnosis with a simple physical exam. Symptoms of psoriasis are typically evident and easy to distinguish from other conditions that may cause similar symptoms.

During this exam, be sure to show your doctor all areas of concern. In addition, let your doctor know if any family members have the condition.

If the symptoms are unclear or if your doctor wants to confirm their suspected diagnosis, they may take a small sample of skin. This is known as a biopsy.

The skin will be sent to a lab, where itll be examined under a microscope. The examination can diagnose the type of psoriasis you have. It can also rule out other possible disorders or infections.

Most biopsies are done in your doctors office the day of your appointment. Your doctor will likely inject a local numbing medication to make the biopsy less painful. They will then send the biopsy to a lab for analysis.

When the results return, your doctor may request an appointment to discuss the findings and treatment options with you.

External triggers may start a new bout of psoriasis. These triggers arent the same for everyone. They may also change over time for you.

The most common triggers for psoriasis include:

Unusually high stress may trigger a flare-up. If you learn to reduce and manage your stress, you can reduce and possibly prevent flare-ups.

Heavy alcohol use can trigger psoriasis flare-ups. If you excessively use alcohol, psoriasis outbreaks may be more frequent. Reducing alcohol consumption is smart for more than just your skin too. Your doctor can help you form a plan to quit drinking if you need help.

An accident, cut, or scrape may trigger a flare-up. Shots, vaccines, and sunburns can also trigger a new outbreak.

Some medications are considered psoriasis triggers. These medications include:

Psoriasis is caused, at least in part, by the immune system mistakenly attacking healthy skin cells. If youre sick or battling an infection, your immune system will go into overdrive to fight the infection. This might start another psoriasis flare-up. Strep throat is a common trigger.

Here are 10 more psoriasis triggers you can avoid.

Psoriasis has no cure. Treatments aim to reduce inflammation and scales, slow the growth of skin cells, and remove plaques. Psoriasis treatments fall into three categories:

Creams and ointments applied directly to the skin can be helpful for reducing mild to moderate psoriasis.

Topical psoriasis treatments include:

People with moderate to severe psoriasis, and those who havent responded well to other treatment types, may need to use oral or injected medications. Many of these medications have severe side effects. Doctors usually prescribe them for short periods of time.

These medications include:

This psoriasis treatment uses ultraviolet (UV) or natural light. Sunlight kills the overactive white blood cells that are attacking healthy skin cells and causing the rapid cell growth. Both UVA and UVB light may be helpful in reducing symptoms of mild to moderate psoriasis.

Most people with moderate to severe psoriasis will benefit from a combination of treatments. This type of therapy uses more than one of the treatment types to reduce symptoms. Some people may use the same treatment their entire lives. Others may need to change treatments occasionally if their skin stops responding to what theyre using.

Learn more about your treatment options for psoriasis.

If you have moderate to severe psoriasis or if psoriasis stops responding to other treatments your doctor may consider an oral or injected medication.

The most common oral and injected medications used to treat psoriasis include:

This class of medications alters your immune system and prevents interactions between your immune system and inflammatory pathways. These medications are injected or given through intravenous (IV) infusion.

Retinoids reduce skin cell production. Once you stop using them, symptoms of psoriasis will likely return. Side effects include hair loss and lip inflammation.

People who are pregnant or may become pregnant within the next three years shouldnt take retinoids because of the risk of possible birth defects.

Cyclosporine (Sandimmune) prevents the immune systems response. This can ease symptoms of psoriasis. It also means you have a weakened immune system, so you may become sick more easily. Side effects include kidney problems and high blood pressure.

Like cyclosporine, methotrexate suppresses the immune system. It may cause fewer side effects when used in low doses. It can cause serious side effects in the long term. Serious side effects include liver damage and reduced production of red and white blood cells.

Learn more about the oral medications used to treat psoriasis.

Food cant cure or even treat psoriasis, but eating better might reduce your symptoms. These five lifestyle changes may help ease symptoms of psoriasis and reduce flare-ups:

If youre overweight, losing weight may reduce the conditions severity. Losing weight may also make treatments more effective. Its unclear how weight interacts with psoriasis, so even if your symptoms remain unchanged, losing weight is still good for your overall health.

Reduce your intake of saturated fats. These are found in animal products like meats and dairy. Increase your intake of lean proteins that contain omega-3 fatty acids, such as salmon, sardines, and shrimp. Plant sources of omega-3s include walnuts, flax seeds, and soybeans.

Psoriasis causes inflammation. Certain foods cause inflammation too. Avoiding those foods might improve symptoms. These foods include:

Alcohol consumption can increase your risks of a flare-up. Cut back or quit entirely. If you have a problem with your alcohol use, your doctor can help you form a treatment plan.

Some doctors prefer a vitamin-rich diet to vitamins in pill form. However, even the healthiest eater may need help getting adequate nutrients. Ask your doctor if you should be taking any vitamins as a supplement to your diet.

Learn more about your dietary options.

Life with psoriasis can be challenging, but with the right approach, you can reduce flare-ups and live a healthy, fulfilling life. These three areas will help you cope in the short- and long-term:

Losing weight and maintaining a healthy diet can go a long way toward helping ease and reduce symptoms of psoriasis. This includes eating a diet rich in omega-3 fatty acids, whole grains, and plants. You should also limit foods that may increase your inflammation. These foods include refined sugars, dairy products, and processed foods.

There is anecdotal evidence that eating nightshade fruits and vegetables can trigger psoriasis symptoms. Nightshade fruits and vegetables include tomatoes as well as white potatoes, eggplants, and pepper-derived foods like paprika and cayenne pepper (but not black pepper, which comes from a different plant altogether).

Stress is a well-established trigger for psoriasis. Learning to manage and cope with stress may help you reduce flare-ups and ease symptoms. Try the following to reduce your stress:

People with psoriasis are more likely to experience depression and self-esteem issues. You may feel less confident when new spots appear. Talking with family members about how psoriasis affects you may be difficult. The constant cycle of the condition may be frustrating too.

All of these emotional issues are valid. Its important you find a resource for handling them. This may include speaking with a professional mental health expert or joining a group for people with psoriasis.

Learn more about living with psoriasis.

Between 30 and 33 percent of people with psoriasis will receive a diagnosis of psoriatic arthritis, according to recent clinical guidelines from the AAD and the NPF.

This type of arthritis causes swelling, pain, and inflammation in affected joints. Its commonly mistaken for rheumatoid arthritis or gout. The presence of inflamed, red areas of skin with plaques usually distinguishes this type of arthritis from others.

Psoriatic arthritis is a chronic condition. Like psoriasis, the symptoms of psoriatic arthritis may come and go, alternating between flare-ups and remission. Psoriatic arthritis can also be continuous, with constant symptoms and issues.

This condition typically affects joints in the fingers or toes. It may also affect your lower back, wrists, knees, or ankles.

Most people who develop psoriatic arthritis have psoriasis. However, its possible to develop the joint condition without having a psoriasis diagnosis. Most people who receive an arthritis diagnosis without having psoriasis have a family member who does have the skin condition.

Treatments for psoriatic arthritis may successfully ease symptoms, relieve pain, and improve joint mobility. As with psoriasis, losing weight, maintaining a healthy diet, and avoiding triggers may also help reduce psoriatic arthritis flare-ups. An early diagnosis and treatment plan can reduce the likelihood of severe complications, including joint damage.

Learn more about psoriatic arthritis.

Around 7.4 million people in the United States have psoriasis.

Psoriasis may begin at any age, but most diagnoses occur in adulthood. The average age of onset is between 15 to 35 years old. According to the World Health Organization (WHO), some studies estimate that about 75 percent of psoriasis cases are diagnosed before age 46. A second peak period of diagnoses can occur in the late 50s and early 60s.

According to WHO, males and females are affected equally. White people are affected disproportionately. People of color make up a very small proportion of psoriasis diagnoses.

Having a family member with the condition increases your risk for developing psoriasis. However, many people with the condition have no family history at all. Some people with a family history wont develop psoriasis.

Around one-third of people with psoriasis will be diagnosed with psoriatic arthritis. In addition, people with psoriasis are more likely to develop conditions such as:

Though the data isnt complete, research suggests cases of psoriasis are becoming more common. Whether thats because people are developing the skin condition or doctors are just getting better at diagnosing is unclear.

Check out more statistics about psoriasis.

Read the original post:

Psoriasis: Causes, Triggers, Treatment, and More

Psoriasis – Symptoms and causes – Mayo Clinic

Overview How psoriasis develops Open pop-up dialog box

Close

In psoriasis, the life cycle of your skin cells greatly accelerates, leading to a buildup of dead cells on the surface of the epidermis.

Psoriasis is a skin disease that causes red, itchy scaly patches, most commonly on the knees, elbows, trunk and scalp.

Psoriasis is a common, long-term (chronic) disease with no cure. It tends to go through cycles, flaring for a few weeks or months, then subsiding for a while or going into remission. Treatments are available to help you manage symptoms. And you can incorporate lifestyle habits and coping strategies to help you live better with psoriasis.

Close

Plaque psoriasis is the most common type of psoriasis. It usually causes dry, red skin lesions (plaques) covered with silvery scales.

Close

Guttate psoriasis, more common in children and adults younger than 30, appears as small, water-drop-shaped lesions on the trunk, arms, legs and scalp. The lesions are typically covered by a fine scale.

Close

Psoriasis causes red patches of skin covered with silvery scales and a thick crust on the scalp most often extending just past the hairline that may bleed when removed.

Close

Inverse psoriasis causes smooth patches of red, inflamed skin. It's more common in overweight people and is worsened by friction and sweating.

Close

Psoriasis can affect fingernails and toenails, causing pitting, abnormal nail growth and discoloration.

Close

Pustular psoriasis generally develops quickly, with pus-filled blisters appearing just hours after your skin becomes red and tender. It can occur in widespread patches or in smaller areas on your hands, feet or fingertips.

Close

The least common type of psoriasis, erythrodermic psoriasis can cover your entire body with a red, peeling rash that can itch or burn intensely.

Psoriasis signs and symptoms can vary from person to person. Common signs and symptoms include:

Psoriasis patches can range from a few spots of dandruff-like scaling to major eruptions that cover large areas. The most commonly affected areas are the lower back, elbows, knees, legs, soles of the feet, scalp, face and palms.

Most types of psoriasis go through cycles, flaring for a few weeks or months, then subsiding for a time or even going into remission.

There are several types of psoriasis, including:

If you suspect that you may have psoriasis, see your doctor. Also, talk to your doctor if your psoriasis:

Viven Williams: Your fingernails are clues to your overall health. Many people develop lines or ridges from the cuticle to the tip.

Rachel Miest, M.D.: Those are actually completely fine and just a part of normal aging.

Viven Williams: But Dr. Rachel Miest says there are other nail changes you should not ignore that may indicate

Rachel Miest, M.D.: liver problems, kidney problems, nutritional deficiencies ...

Viven Williams: and other issues. Here are six examples: No. 1 is pitting. This could be a sign of psoriasis. Two is clubbing. Clubbing happens when your oxygen is low and could be a sign of lung issues. Three is spooning. It can happen if you have iron-deficient anemia or liver disease. Four is called "a Beau's line." It's a horizontal line that indicates a previous injury or infection. Five is nail separation. This may happen as a result of injury, infection or a medication. And six is yellowing of the nails, which may be the result of chronic bronchitis.

For the Mayo Clinic News Network, I'm Vivien Williams.

Psoriasis is thought to be an immune system problem that causes the skin to regenerate at faster than normal rates. In the most common type of psoriasis, known as plaque psoriasis, this rapid turnover of cells results in scales and red patches.

Just what causes the immune system to malfunction isn't entirely clear. Researchers believe both genetics and environmental factors play a role. The condition is not contagious.

Many people who are predisposed to psoriasis may be free of symptoms for years until the disease is triggered by some environmental factor. Common psoriasis triggers include:

Anyone can develop psoriasis. About a third of instances begin in the pediatric years. These factors can increase your risk:

If you have psoriasis, you're at greater risk of developing other conditions, including:

See more here:

Psoriasis - Symptoms and causes - Mayo Clinic

Psoriasis – Diagnosis and treatment – Mayo Clinic

Diagnosis

Your doctor will ask questions about your health and examine your skin, scalp and nails. Your doctor might take a small sample of skin (biopsy) for examination under a microscope. This helps determine the type of psoriasis and rule out other disorders.

Psoriasis treatments aim to stop skin cells from growing so quickly and to remove scales. Options include creams and ointments (topical therapy), light therapy (phototherapy), and oral or injected medication.

Which treatments you use depends on how severe the psoriasis is and how responsive it has been to previous treatment. You might need to try different drugs or a combination of treatments before you find an approach that works for you. Usually, however, the disease returns.

Corticosteroids. These drugs are the most frequently prescribed medications for treating mild to moderate psoriasis. They are available as ointments, creams, lotions, gels, foams, sprays and shampoos. Mild corticosteroid ointments (hydrocortisone) are usually recommended for sensitive areas, such as your face or skin folds, and for treating widespread patches. Topical corticosteroids might be applied once a day during flares, and on alternate days or weekends only to maintain remission.

Your doctor may prescribe a stronger corticosteroid cream or ointment triamcinolone (Acetonide, Trianex), clobetasol (Temovate) for smaller, less-sensitive or tougher-to-treat areas.

Long-term use or overuse of strong corticosteroids can thin the skin. Over time, topical corticosteroids may stop working.

Retinoids. Tazarotene (Tazorac, Avage) is available as a gel and cream and applied once or twice daily. The most common side effects are skin irritation and increased sensitivity to light.

Tazarotene isn't recommended when you're pregnant or breast-feeding or if you intend to become pregnant.

Calcineurin inhibitors. Calcineurin inhibitors such as tacrolimus (Protopic) and pimecrolimus (Elidel) reduce inflammation and plaque buildup. They can be especially helpful in areas of thin skin, such as around the eyes, where steroid creams or retinoids are too irritating or may cause harmful effects.

Calcineurin inhibitors are not recommended when you're pregnant or breast-feeding or if you intend to become pregnant. This drug is also not intended for long-term use because of a potential increased risk of skin cancer and lymphoma.

Coal tar. Coal tar reduces scaling, itching and inflammation. It's available over-the-counter or by prescription in various forms, such as shampoo, cream and oil. These products can irritate the skin. They're also messy, stain clothing and bedding, and can have a strong odor.

Coal tar treatment isn't recommended for women who are pregnant or breast-feeding.

Light therapy is a first-line treatment for moderate to severe psoriasis, either alone or in combination with medications. It involves exposing the skin to controlled amounts of natural or artificial light. Repeated treatments are necessary. Talk with your doctor about whether home phototherapy is an option for you.

Psoralen plus ultraviolet A (PUVA). This treatment involves taking a light-sensitizing medication (psoralen) before exposure to UVA light. UVA light penetrates deeper into the skin than does UVB light, and psoralen makes the skin more responsive to UVA exposure.

This more aggressive treatment consistently improves skin and is often used for more-severe cases of psoriasis. Short-term side effects include nausea, headache, burning and itching. Long-term side effects include dry and wrinkled skin, freckles, increased sun sensitivity, and increased risk of skin cancer, including melanoma.

If you have moderate to severe psoriasis or other treatments haven't worked, your doctor may prescribe oral or injected (systemic) drugs. Because of the potential for severe side effects, some of these medications are used for only brief periods and might be alternated with other treatments.

Methotrexate. Usually administered weekly as a single oral dose, methotrexate (Trexall) decreases the production of skin cells and suppresses inflammation. It's less effective than adalimumab (Humira) and infliximab (Remicade). It might cause upset stomach, loss of appetite and fatigue. People taking methotrexate long term need ongoing testing to monitor their blood counts and liver function.

Men and women should stop taking methotrexate at least three months before attempting to conceive. This drug is not recommended when you're breast-feeding.

Cyclosporine. Taken orally for severe psoriasis, cyclosporine (Neoral) suppresses the immune system. It's similar to methotrexate in effectiveness but cannot be used continuously for more than a year. Like other immunosuppressant drugs, cyclosporine increases your risk of infection and other health problems, including cancer. People taking cyclosporine need ongoing monitoring of their blood pressure and kidney function.

These drugs are not recommended when you're pregnant, breast-feeding or if you intend to become pregnant.

Biologics. These drugs, usually administered by injection, alter the immune system in a way that disrupts the disease cycle and improves symptoms and signs of disease within weeks. Several of these drugs are approved for the treatment of moderate to severe psoriasis in people who haven't responded to first-line therapies. The therapeutic options are rapidly expanding. Examples include etanercept (Enbrel), infliximab (Remicade), adalimumab (Humira), ustekinumab (Stelara), secukinumab (Cosentyx) and ixekizumab (Taltz). These types of drugs are expensive and may or may not be covered by health insurance plans.

Biologics must be used with caution because they carry the risk of suppressing your immune system in ways that increase your risk of serious infections. In particular, people taking these treatments must be screened for tuberculosis.

Although doctors choose treatments based on the type and severity of psoriasis and the areas of skin affected, the traditional approach is to start with the mildest treatments topical creams and ultraviolet light therapy (phototherapy) in people with typical skin lesions (plaques) and then progress to stronger ones only if necessary. People with pustular or erythrodermic psoriasis or associated arthritis usually need systemic therapy from the beginning of treatment. The goal is to find the most effective way to slow cell turnover with the fewest possible side effects.

A number of alternative therapies claim to ease the symptoms of psoriasis, including special diets, creams, dietary supplements and herbs. None have definitively been proved effective. But some alternative therapies are deemed generally safe and might reduce itching and scaling in people with mild to moderate psoriasis. Other alternative therapies are useful in avoiding triggers, such as stress.

If you're considering dietary supplements or other alternative therapy to ease the symptoms of psoriasis, consult your doctor. He or she can help you weigh the pros and cons of specific alternative therapies.

Explore Mayo Clinic studies testing new treatments, interventions and tests as a means to prevent, detect, treat or manage this disease.

Try these self-care measures to better manage your psoriasis and feel your best:

Coping with psoriasis can be a challenge, especially if the affected skin covers a large area of your body or is visible to other people. The ongoing, persistent nature of the disease and the treatment challenges only add to the burden.

Here are some ways to help you cope and to feel more in control:

You'll likely first see your family doctor or a general practitioner. In some cases, you may be referred directly to a specialist in skin diseases (dermatologist).

Here's some information to help you prepare for your appointment and to know what to expect from your doctor.

Make a list of the following:

For psoriasis, some basic questions you might ask your doctor include:

Your doctor is likely to ask you several questions, such as:

Go here to read the rest:

Psoriasis - Diagnosis and treatment - Mayo Clinic

Psoriasis: Types, Pictures, Causes, Symptoms, Treatments …

Alwan, W., and F.O. Nestle. "Pathogenesis and Treatment of Psoriasis: Exploiting Pathophysiological Pathways for Precision Medicine." Clin Exp Rheumatol 33 (Suppl. 93): S2-S6.

Arndt, Kenneth A., eds., et al. "Topical Therapies for Psoriasis." Seminars in Cutaneous Medicine and Surgery 35.2S Mar. 2016: S35-S46.

Benhadou, Fairda, Dillon Mintoff, and Vronique del Marmol. "Psoriasis: Keratinocytes or Immune Cells -- Which Is the Trigger?" Dermatology Dec. 19, 2018.

Conrad, Curdin, Michel Gilliet. "Psoriasis: From Pathogenesis to Targeted Therapies." Clinical Reviews in Allergy & Immunology Jan. 18, 2015.

Dowlatshahi, E.A., E.A.M van der Voort, L.R. Arends, and T. Nijsten. "Markers of Systemic Inflammation in Psoriasis: A Systematic Review and Meta-Analysis." British Journal of Dermatology 169.2 Aug. 2013: 266-282.

Georgescu, Simona-Roxana, et al. "Advances in Understanding the Immunological Pathways in Psoriasis." International Journal of Molecular Sciences 20.739 Feb. 10, 2019: 2-17.

Greb, Jacqueline E., et al. "Psoriasis." Nature Reviews Disease Primers 2 (2016): 1-17.

Kaushik, Shivani B., and Mark G. Lebwohl. "Review of Safety and Efficacy of Approved Systemic Psoriasis Therapies." International Journal of Dermatology 2018.

National Psoriasis Foundation. "Systemic Treatments: Biologics and Oral Treatments." 1-25.

Ogawa, Eisaku, Yuki Sato, Akane Minagawa, and Ryuhei Okuyama. "Pathogenesis of Psoriasis and Development of Treatment." The Journal of Dermatology 2017: 1-9.

Stiff, Katherine M., Katelyn R. Glines, Caroline L. Porter, Abigail Cline & StevenR. Feldman. "Current pharmacological treatment guidelines for psoriasis and psoriaticarthritis." Expert Review of Clinical Pharmacology (2018).

Villaseor-Park, Jennifer, David Wheeler, and Lisa Grandinetti. "Psoriasis: Evolving Treatment for a Complex Disease." Cleveland Clinic Journal of Medicine 79.6 June 2012: 413-423.

Woo, Yu Ri, Dae Ho Cho, and Hyun Jeong Park. "Molecular Mechanisms and Management of a Cutaneous Inflammatory Disorder: Psoriasis." International Journal of Molecular Sciences 18 Dec. 11, 2017: 1-26.

Read this article:

Psoriasis: Types, Pictures, Causes, Symptoms, Treatments ...

Psoriasis Awareness Month: Cyndi Lauper slept in a rubber suit for three nights straight to beat the disease – MEAWW

Cyndi Lauper was diagnosed with psoriasis, an auto-immune chronic disorder, in 2010. The condition leads to red and raised patches lined by silvery scales on the skin and for Lauper, it started with her scalp which she at first thought must be because of bugs. "I had this kind of buildup on my scalp, which, because my son played hockey at the time, I thought Oh, it might be bugs (from the hockey players). Id never had bugs. Then I went to the doctor and he said, 'No, no, no, thats plaque psoriasis,'" she said in an interview with Health.

She always had good skin while growing up but after her diagnosis, she started to lose hope of feeling good in her skin ever again. As a singer who is constantly on the go, the disease pulled her down really hard. "Youre tired. Its an inflammatory disease so it kind of zaps your strength. And trying to sing, work out, and have all this (clothing) on, and then taking it off, your skin comes with it. Its awful. Emotionally, honestly, at the height of being that sick, you feel very much alone." After trying out cortisone creams, she realized that the side-effects of it were too much to deal with and that is when she turned to traditional medicine.

"Now I can get back to the things I like to do, like singing and going on tour. After I started the medicine, psoriasis started to go away, and I couldnt even believe it. I was always on eggshells. I still lather up with cream and am nervous because I dont want to go back to that," she said. Lauper also advocates seeking medical assistance and self-care for people affected by this condition. She spoke about the importance of the same elaborately in an awareness video by the National Psoriasis Foundation in 2015. In the video, she says that she tried every method in the book including the time she slept in a rubber suit with cream on for three nights straight, a measure taken upon a doctor's advice that happened to eventually work for her.

The reason why she lends her voice to Psoriasis awareness is that she believes the condition "is one of those things that no one wants to talk about, which makes it something I want to talk about". As a word of advice for people with psoriasis, she said, "Its not just a rash. Dont let it go. Get information. Knowledge is power." She also advocates taking measures for taking steps to keep one's mental health in check as the disease affects more than just the skin. "Youre hurting inside because you feel powerless and information is power. Help yourself. Dont just sit in the dark," she said.

August is Psoriasis Awareness Month and it brings an opportunity for survivors and activists to share tips and raise awareness about the genetic disease. In this column, we highlight the struggles of celebrities and talk about preventative and cure measures.

Here is the original post:

Psoriasis Awareness Month: Cyndi Lauper slept in a rubber suit for three nights straight to beat the disease - MEAWW

Psoriasis Treatment Market Size to Witness a CAGR Exceeding 7.3% By 2025 | Growth Insights, COVID-19 Impact, Share Estimation and Future Trends -…

(MENAFN - GetNews) Psoriasis Treatment Market Size, Trends and Growth Analysis by Drug Class [Tumour Necrosis Factor Inhibitors (Adalimumab, Infliximab and Etanercept), Interleukin-Inhibitors (Ustekinumab, Secukinumab, Ixekizumab and Brodalumab), Vitamin D Analogues (Calcitriol, Calcipotriol and Tacalcitol)], Treatment Type and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2025

Psoriasis Treatment Market Overview

The Global Psoriasis Treatment Market is growing rapidly. The market growth attributes o the availability of several breakthrough therapeutics and drugs to treat symptoms of psoriasis. Over recent years, technological advancements have brought notable innovations in psoriasis treatments, offering phenomenal relief and benefitting results. These improvements increase the psoriasis market size, proving to be a boon to the patients by improving their quality of life.

According to Market Research Future (MRFR), the global psoriasis treatment market size is expected to reach USD 13.1 Billion by 2025, growing at 7.3% CAGR during the review period (2019-2025). Rising prevalence rate of psoriasis is one of the prime factors propelling market growth. Besides, the availability of breakthrough psoriasis drugs on the market fosters the growth of the market. Valuation of the market is anticipated to progress massively in the near future, witnessing the emergence of many new treatments.

Request Free Sample Copy at: [To enable links contact MENAFN]

The increasing demand for effective psoriasis treatments pushes the market growth of the market to the ascended level. Conversely, the lack of awareness and unmet medical needs are the major factors expected to obstruct the market growth. Nevertheless, growing technology upgrades would support market growth throughout the assessment period. Furthermore, the increased funding for research and development from the public and private sectors would provide impetus to the market growth.

Psoriasis Treatment Market Segmentations

By Drug Class : Tumour Necrosis Factor Inhibitors (Adalimumab, Infliximab, Etanercept), K.in-Inhibitors (Ustekinumab, K.inumab, Ixekizumab, Brodalumab), Vitamin D Analogues (Calcitriol, Calcipotriol, Tacalcitol), and others.

By Treatment Type: Topicals (Over the Counter (OTC) Topicals, Topical Non-Steroids, Topical Steroids), Systemic (Retinoid, Cyclosporine, Methotrexate), Biologics (Tumour Necrosis Factor Alpha (TNF-a) Inhibitors, K.in 12 and 23 (IL-12/23) Inhibitors, K.in 17 (IL-17) Inhibitor, T Cell Inhibitor), and others.

Psoriasis Treatment Market Regional Outlook

North America dominates the global psoriasis treatments market. The largest market share attributes to the rising prevalence of psoriasis among children as well as adults. Besides, the strong presence of notable players and well-established treatment centers in the region impact the market growth positively. Moreover, high per capita healthcare expenditures and early adoption of new technology in the region substantiate the regional market growth. High cases of psoriasis in the US and Canada is expected to drive the market growth. The North American psoriasis treatments market is projected to retain its dominance over the global market throughout the forecast period.

Europe stands second in the global psoriasis treatment market. Positive amendments in the reimbursement policies drive the market. Furthermore, increasing expenses in research by healthcare bodies fuel the growth of the market in this region. Also, rising healthcare expenses allow the market to showcase a considerable amount of growth.

Additionally, the presence of a well-established healthcare system and key industry players, alongside technology upgrades in medical devices and therapeutics, drives the regional market growth. The European psoriasis treatments market is expected to create a substantial revenue pocket over the assessment period.

The Asia Pacific psoriasis treatments market is growing rapidly. Factors such as the increasing demand for spine surgeries and increasing government initiatives for healthcare reforms boost the regional market growth. Besides, a large patient pool and expansion of healthcare in the region drive the growth of the market. Furthermore, growing per capita healthcare expenditures and developing economies provide an impetus to the regional market. The APAC psoriasis treatments market is projected to have a steady growth rate during the forecast period.

Psoriasis Treatment Market Competitive Analysis

Highly competitive, the global psoriasis treatment appears fragmented due to the presence of several well-established industry players. These players adopt strategic initiatives such as mergers & acquisitions, collaborations, expansion, and technology launch to gain a larger competitive advantage. Psoriasis pharmaceutical companies invest substantially in R & D and clinical trials to develop effective drugs and therapeutics.

Psoriasis pharmaceutical companies collaborate with a number of partners from academia to the biotech industry who contribute specialized knowledge and cutting-edge technologies to accelerate pharmaceutical innovations and gain a better understanding of the condition. These collaborations form one of the pillars of the company's innovation strategy. Through partnerships, companies can leverage scientific know-how and use it for innovative medicines. Partnerships can leverage innovative impulses that advance medicine and benefit patients and partners.

Major Players:

Players leading the psoriasis treatment market include UCB (Belgium), Novartis International AG (Switzerland), AstraZeneca (UK), Johnson & Johnson (US), Celgene Corporation (US), Pfizer Inc (US), AbbVie (US), Merck and Co. Inc (US), Eli Lilly and Company (US), and Amgen (US), among others.

Browse Detailed TOC with COVID-19 Impact Analysis at: [To enable links contact MENAFN]

Industry/Innovation/ Related News:

A team of researchers at John A. Paulson School of Engineering and Applied Sciences (SEAS) and Harvard's Wyss Institute for Biologically Inspired Engineering published their study, stating that siRNA-based treatment can reduce psoriasis symptoms significantly.

Scientists circumvented limitations by using an ionic liquid (IL) combination to deliver a small interfering RNA (siRNA)-based treatment successfully to the skin in a mouse model of psoriasis, significantly reducing levels of inflammatory cytokines and symptoms of psoriasis without systemic side effects.

Browse More Healthcare Related Research Report at:

Contact Lenses Market Research Report - Global Forecast till 2025 [To enable links contact MENAFN]

NOTE: Our team of researchers are studying Covid19 and its impact on various industry verticals and wherever required we will be considering covid19 footprints for a better analysis of markets and industries. Cordially get in touch for more details.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Media Contact Company Name: Market Research Future Contact Person: Abhishek Sawant Email: Send Email Phone: +1 646 845 9312 Address: Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar City: Pune State: Maharashtra Country: India Website: [To enable links contact MENAFN]

Originally posted here:

Psoriasis Treatment Market Size to Witness a CAGR Exceeding 7.3% By 2025 | Growth Insights, COVID-19 Impact, Share Estimation and Future Trends -...

The Journal of Drugs in Dermatology Publishes Results from Positive Phase 1/2a Trial of Arcutis’ ARQ-151 (Topical Roflumilast Cream) for the Treatment…

WESTLAKE VILLAGE, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology, announced today that The Journal of Drugs in Dermatology has published positive results from a Phase 1/2a trial of its investigational drug topical roflumilast cream for the treatment of chronic plaque psoriasis. The article has been published in the August 2020 issue of the journal. These results demonstrate that ARQ-151 (roflumilast cream) was safe and highly effective at doses of 0.5% and 0.15%, and represents a potential novel once-daily topical therapy for the treatment of chronic plaque psoriasis.

Psoriasis imposes a high burden for patients, and current standards of care to treat this skin disease often carry significant treatment limitations, resulting in poor outcomes. Poor outcomes often have a negative impact on patient quality of life, said Kim A. Papp, MD, PhD, of Probity Medical Research and K. Papp Clinical Research Inc., and lead author of the publication. Roflumilast once-daily cream demonstrated significant improvements in psoriasis signs and symptoms. Notably, roflumilast cream demonstrated favorable tolerability, without any patient discontinuation due to adverse events. The positive results from this study are encouraging for patients and clinicians who are desperate for a new topical treatment solution that will simplify disease management and improve the patient experience. Enabling patients with more effective chronic treatment in all areas of the body is our hope.

Roflumilast cream (ARQ-151) is a once-daily, highly potent, selective phosphodiesterase-4 (PDE-4) inhibitor being developed for chronic plaque psoriasis. Arcutis is currently conducting a Phase 3 clinical program with topical roflumilast cream, including two ongoing pivotal Phase 3 clinical trials (DERMIS-1 and -2). The company anticipates topline data from the Phase 3 studies in the first half of 2021.

The Phase 1/2a study assessed the safety and efficacy of once-daily roflumilast cream 0.5% and 0.15% in patients with chronic plaque psoriasis. The study enrolled a single-dose, open-label Phase 1 cohort (0.5% cream applied to 25 cm2 psoriatic plaques), and a 28-day, double-blinded Phase 2a cohort (1:1:1 randomization to roflumilast cream 0.5%, 0.15%, or vehicle). Patients had chronic plaque psoriasis of > 6 months duration with 5% body surface area involvement. Outcomes included safety (adverse events) and efficacy (percentage change in the product of Target Plaque Severity Score [TPSS] and Target Plaque Area [TPA]) at week 4.

For Cohorts 1 (n=8) and 2 (n=89), adverse events (all mild/moderate; none serious or severe) were similar between active arms and vehicle. Treatment-related events were confined to the application site, with no difference between active and vehicle. No patient discontinued treatment due to adverse events. The primary efficacy endpoint was met for both roflumilast cream doses: TPSSTPA improvement at week 4 was statistically significant for roflumilast 0.5% (P=0.0007) and 0.15% (P=0.0011) versus vehicle; significance was reached as early as 2 weeks. For both roflumilast cream doses, 66% to 67% improvement from baseline was observed at week 4, without reaching a plateau, versus 38% improvement for vehicle.

The results from this Phase 1/2a study provide further evidence of the potential of roflumilast cream as a once-daily treatment for patients with plaque psoriasis who currently lack suitable treatment options, and who often have to settle for trade-offs in drug efficacy, safety, and tolerability, said Frank Watanabe, Arcutis President and Chief Executive Officer. We believe that topical roflumilast has the potential to deliver the efficacy that enables meaningful symptomatic improvement and a safety and tolerability profile that supports chronic use and the ability to use in all body areas.

Please refer to the paper, Roflumilast Cream Improves Signs and Symptoms of Plaque Psoriasis: Results from a Phase 1/2a Randomized, Controlled Study for the full description of the design and results of this study.

About ARQ-151 (Topical Roflumilast Cream)Topical roflumilast cream is a once-daily, topical cream formulation containing roflumilast, a PDE4 inhibitor, that Arcutis is developing to treat plaque psoriasis, including intertriginous psoriasis, and atopic dermatitis. PDE4 is an intracellular enzyme that regulates pro-inflammatory and anti-inflammatory cytokine production and cell proliferation. Roflumilast was approved by the FDA for systemic treatment to reduce risk of exacerbation of chronic obstructive pulmonary disease (COPD) in 2011, has shown greater potency (25 - 300 fold) than other two FDA-approved PDE4 inhibitors used in dermatology.

About PsoriasisPsoriasis is an immune disease that occurs in about two percent of adults in western countries. About 90% of psoriasis cases is plaque psoriasis, which is characterized by plaques, or raised, red areas of skin covered with a silver or white layer of scale. Psoriatic plaques can appear on any area of the body, but most often appear on the scalp, knees, elbows, trunk, and limbs, and the plaques are often itchy and sometimes painful. Plaques in certain anatomical areas present particular treatment challenges, including the face, elbows and knees, scalp, and intertriginous areas (where two skin areas may touch or rub together).

About Arcutis - Bioscience, applied to the skin.Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. Arcutis robust pipeline includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The companys lead product candidate, topical roflumilast, has the potential to revitalize the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. For more information, visit https://www.arcutis.com or follow the company on LinkedIn and Twitter.

Contacts:Investor Relations:Heather Rowe ArmstrongVice President, Investor Relations & Corporate Communicationsharmstrong@arcutis.com805-418-5006, Ext. 740

View post:

The Journal of Drugs in Dermatology Publishes Results from Positive Phase 1/2a Trial of Arcutis' ARQ-151 (Topical Roflumilast Cream) for the Treatment...

Treating the Mental and Physical Symptoms of Psoriasis – Allure

For the eight million Americans living with psoriasis, the mental impact can be as great as the physical one. A dermatologist and psychologist weigh in on why treatment must address both burdens.

This story originally appeared in the August 2020 issue of Allure. Learn how tosubscribe here.

By Joel Gelfand, a professor of dermatology and epidemiology at the University of Pennsylvania Perelman School of Medicine and director of the schools Psoriasis and Phototherapy Treatment Center.

I worked on a survey that found 30-40 percent of people in the United States think psoriasis is contagious they dont want to shake the hand of someone with psoriasis. Think about that. If one in every three people that you run into on the street is going to have that view of your skin, thats a really challenging thing to cope with. Psoriasis can be socially isolating and cause people to feel anxious and depressed.

Psoriasis is not contagious. Its a common autoimmune disease of the skin, in which your body recognizes a normal skin protein as abnormal and tries to get rid of it by making skin flake off. This results in large, thick, scaly plaques that crack and bleed, and can be painful and itchy. The areas it impacts can vary, but some of the most sensitive are the scalp, face, genitals, and fingernails. A lot of patients wont wear short sleeves or shorts because their knees or elbows are affected. The typical onset is in young adulthood, but Ive seen it in infants all the way up to a patient in her 80s, who experienced it for the first time after her sister died. Studies have shown that people facing major life events are at higher risk of developing psoriasis, and that patients with psoriasis report higher levels of stress. Theres a cyclical relationship.

As tough a disease as psoriasis is, we do have a variety of ways of treating it. It can take weeks or months to see results. When the disease is localized, people like topical medications, which decrease the growth of excess skin cells [that make up psoriasis plaques]. But they may not work for some patients, and theyre inconvenient, especially if a lot of areas are affected. Pills can reduce the overactive immune response, but some can prompt gastrointestinal symptoms. Injectable medications, called biologics, are highly effective but expensive, and can make people slightly more prone to infection because they decrease immune activity in the body. My lab is researching at-home UV phototherapy, which would be more widely available than office-based ones.

Visit link:

Treating the Mental and Physical Symptoms of Psoriasis - Allure

Avoid these foods and drinks if you have psoriasis – TheHealthSite

Psoriasis impacts millions of people worldwide. It is a skin condition that causes cells to build up on the skins surface, leading to the appearance of itchy and dry, and painful red patches.While there is no strong evidence linking diet to psoriasis flare-ups, many sufferers reported worsening of their symptoms after eating certain foods and drinks. A review of 55 studies that included more than 4,500 people living with psoriasis recommended limiting caloric intake if youre overweight or obese and have the skin condition. Some psoriasis patients may be sensitive to gluten a protein found in grains including rye, barley and wheat. Researchers in Europe found that psoriasis symptoms in these people improved after they removed gluten from their diet. However, its still unclear if gluten-free diets can help all psoriasis patients. Substances in spices and condiments like pimento, curry, cinnamon, vinegar, paprika, Tabasco, Worcestershire sauce and ketchup may also cause inflammation. Some psoriasis patients have reported worsening of their symptoms after consuming these spices and condiments. Below are some other foods and drinks that you may consider cutting out to improve your psoriasis symptoms. But always discuss with your physician before making any dietary changes.

Read more:

Avoid these foods and drinks if you have psoriasis - TheHealthSite


12345...102030...